The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics
Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise, and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.
Download our white paper for insights on:
• First-to-Human antibody therapeutics
• Immunization — PentaMice®️ platform for antibody generation
• Single B cell screening with the Beacon®️ system
• Sequence Identification
• Custom Bioinformatics
• Case Study: Discovery of diverse monoclonal antibodies that bind SARS-CoV-2 Delta and Omicron spike proteins
• Gene-to-Protein Strategies
Offered Free by: Curia Global
See All Resources from: Curia Global
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.